
Promising New Hope for PD-1 Resistant Gastrointestinal Tumors: Marengo Therapeutics Unveils Invikafusp Alfa Data at ESMO GI Congress 2025
Marengo Therapeutics, a clinical-stage immuno-oncology company, has announced encouraging results for its novel investigational therapy, invikafusp alfa, a first-in-class selective dual T-cell agonist. The company presented these findings as a late-breaking oral presentation at the prestigious ESMO Gastrointestinal Cancers Congress 2025, offering a potential new avenue for patients with gastrointestinal (GI) tumors that have become resistant to current PD-1 inhibitor treatments.
The data presented showcased the monotherapy activity of invikafusp alfa in this challenging patient population. This innovative therapy is designed to selectively engage and activate both CD4+ and CD8+ T-cells, which are crucial components of the immune system’s ability to recognize and eliminate cancer cells. By targeting these specific T-cell populations, invikafusp alfa aims to overcome the mechanisms of resistance that often limit the efficacy of existing immunotherapies.
Gastrointestinal cancers, a group that includes notoriously difficult-to-treat conditions like colorectal, gastric, and pancreatic cancers, represent a significant unmet medical need. While PD-1 inhibitors have revolutionized cancer treatment for many, a substantial portion of patients do not respond, or their tumors eventually develop resistance. The development of novel agents that can restore or enhance anti-tumor immunity in these resistant settings is therefore of paramount importance.
The presentation at the ESMO GI Cancers Congress 2025 highlights the scientific community’s recognition of the potential impact of invikafusp alfa. By being selected for a late-breaking oral presentation, Marengo Therapeutics has demonstrated the compelling nature of their findings, suggesting that the data presented has the potential to advance the standard of care for these patients.
While specific details of the clinical trial’s efficacy and safety profile were presented orally, the overarching theme points towards a significant step forward in the fight against PD-1 resistant GI tumors. This development offers a renewed sense of optimism for patients who have exhausted current treatment options and are seeking innovative solutions to combat their disease.
Marengo Therapeutics’ commitment to pioneering novel approaches in immuno-oncology is evident in the development of invikafusp alfa. The company’s focus on selective T-cell activation represents a sophisticated strategy to harness the power of the immune system more effectively. The positive monotherapy results presented at ESMO GI 2025 are a testament to this approach and lay the groundwork for further clinical investigation and potential future approval. This news marks a significant milestone, underscoring the ongoing progress in developing more effective treatments for challenging cancer types.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancers Congress 2025’ at 2025-07-02 14:15. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.